Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Laakso, A. Articles by Hietala, J. Search for Related Content PubMed Citation Articles by Laakso, A. Articles by Hietala, J. Neurotransmitters Schizophrenia Spectrum Disorders PET

Striatal Dopamine Transporter Binding in Neuroleptic-Naive Patients With Schizophrenia Studied With Positron Emission Tomography

OBJECTIVE: Recent in vivo imaging studies indicate a dysregulated presynaptic function of the striatal dopaminergic system in patients with schizophrenia. To further explore the basis of this phenomenon, the authors studied brain dopamine transporter binding in vivo in patients with first-episode, never-medicated schizophrenia. METHOD: Nine patients with schizophrenia and nine healthy matched comparison subjects were recruited. Striatal dopamine transporter binding was measured with positron emission tomography and a specific dopamine transporter ligand, [¹⁸F]CFT, a radiolabeled form of 2ß-carbomethoxy-3ß-(4-fluorophenyl)tropane. RESULTS: Average caudate and putamen dopamine transporter binding potentials were almost identical in the patients and comparison subjects, but the patients lacked the right-left asymmetry of the caudate dopamine transporter binding seen in the comparison group. CONCLUSIONS: Average striatal dopamine transporter density is unaltered in neuroleptic-naive patients with schizophrenia. However, patients lack asymmetry in caudate dopamine transporter binding, which conforms with disrupted brain lateralization in this disorder.

This article has been cited by other articles:

				G. J. E Schmitt, E. M. Meisenzahl, T. Frodl, C. La Fougere, K. Hahn, H- J. Moller, and S. Dresel The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1 J Psychopharmacol, September 1, 2005; 19(5): 488 - 493. [Abstract] [PDF]

				S. N. BHRIAIN, A. W. CLARE, and B. A. LAWLOR Neuroimaging: a new training issue in psychiatry? Psychiatr. Bull., May 1, 2005; 29(5): 189 - 192. [Full Text] [PDF]

				N. J. van der Wee, H. Stevens, J. A. Hardeman, R. C. Mandl, D. A. Denys, H. J. van Megen, R. S. Kahn, and H. M. Westenberg Enhanced Dopamine Transporter Density in Psychotropic-Naive Patients With Obsessive-Compulsive Disorder Shown by [123I]{beta}-CIT SPECT Am J Psychiatry, December 1, 2004; 161(12): 2201 - 2206. [Abstract] [Full Text] [PDF]

				Y. K. Yang, L. Yu, T. L. Yeh, N. T. Chiu, P. S. Chen, and I H. Lee Associated Alterations of Striatal Dopamine D2/D3 Receptor and Transporter Binding in Drug-Naive Patients With Schizophrenia: A Dual-Isotope SPECT Study Am J Psychiatry, August 1, 2004; 161(8): 1496 - 1498. [Abstract] [Full Text] [PDF]

				T. J. Raedler, M. B. Knable, D. W. Jones, R. A. Urbina, J. G. Gorey, K. S. Lee, M. F. Egan, R. Coppola, and D. R. Weinberger In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia Am J Psychiatry, January 1, 2003; 160(1): 118 - 127. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us